HealthyNCT07637487
Tocotrienol Supplementa as A Senolytic Agent in Middle-aged Adults
A study testing Treatment in people with Healthy, run by National University of Malaysia at 1 site in Malaysia.
Trial summary
The goal of this clinical trial is to determine whether tocotrienol works as a senolytic agent to delay age-related biological changes in middle-aged adults. The study will also evaluate the safety of tocotrienol supplementation. Read more about this study
- Who is it for?
- Ages 35 to 50 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- Treatment
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 220 participants
- Where
- 1 siteMalaysia
- Study dates
- 31 Oct 2023to 30 Jan 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 35 to 50 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Generally healthy as assessed by physical examination and blood lab test, including adequate liver and renal function, Neutrophil count > 1500/mm3, Platelet count 120,000 - 450,000/mm3, Haemoglobin concentration 11.5 to 19.0g/dL for men; 10.5-17.5 g/dL for women, Prothrombin and partial thromboplastin time within normal range, ALT and AST < 80 IU/L, Creatinine 0.7 to 1.3 mg/dL
- Subject of either gender, 35 to 64 years of age (inclusive)
- Not allergy to palm oil and vitamin E
- Do not take vitamin E supplements over the past 3 months
- Provide written informed consent prior to screening
- Subject is willing and able to comply with the study visit schedule and procedure, geographic proximity (investigator's discretion) that allows adequate follow up
- Subjects understand the study protocol and signed informed consent forms
Who cannot join
- Subjects with fat malabsorption
- Subjects with chronic conditions such as cardiac diseases (heart failure, myocardial infraction, ischemic heart disease), neurological diseases, diabetes, HIV infection, psychiatric illness/social situations
- Subjects with vegan diet
- Current smoker or used to smoke in the past 3 months
- Subject for surgery or had undergone surgery in the past 3 months
- Current or past history of drug, alcohol abuse and cancer
Show all 11Show fewer
- Pregnant and lactating women
- History of bleeding tendencies or any condition predisposing to bleeding e.g. thrombocytopenia, abnormal liver function, liver disease (e.g. chronic hepatitis), gastrointestinal ulcers
- Any subject taking antibiotics or other medication or dietary supplement which could interfere with the action of tocotrienols
- Subjects who are pre-disposed to inherited blood/circulation disorders
- Subject who is taking anticoagulants and antithrombotic drugs, e.g. warfarin, aspirin, ticlopidine, heparin, etc.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Malaysia1 site, 1 recruiting
- Recruiting
National University of Malaysia
Kuala Lumpur, Kuala Lumpur, 56000
Suzana Makpol, 603-91459554, suzanamakpol@ukm.edu.my
About this study
Official title: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Evaluating Tocotrienol-Rich Fraction as a Senolytic Agent in Middle-Aged Adults
The goal of this clinical trial is to determine whether tocotrienol works as a senolytic agent to delay age-related biological changes in middle-aged adults. The study will also evaluate the safety of tocotrienol supplementation. The main questions it aims to answer are:
Does tocotrienol reduce markers of cellular senescence, inflammation, oxidative stress, and mitochondrial dysfunction?
Read more
What health changes or medical issues occur in participants taking tocotrienol?
Researchers will compare tocotrienol-rich fraction to a placebo (a look-alike capsule with no active ingredient) to determine whether tocotrienol is effective in modulating aging-related pathways.
Participants will:
Take tocotrienol (200 mg/day) or a placebo daily for 6 months
Attend study visits at baseline, 3 months, and 6 months for clinical assessments and laboratory tests
Undergo blood sampling and health evaluations, including measures of senescence-associated secretory phenotype (SASP), inflammation, oxidative stress, mitochondrial function, vascular health, skin status, cognitive function, body composition, and bone mineral density.
Complete questionnaires related to diet throughout the study period
This study aims to provide clinical evidence on the potential of tocotrienol as a senolytic intervention for promoting healthy aging and reducing the risk of age-related diseases.
- Conditions
- Healthy
- Being tested
- Treatment, Placebo
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TreatmentDietary supplement
Each participant will receive 200mg/day of tocotrienol-rich fraction capsules divided into two daily doses
PlaceboOther
Participant will receive placebo softgel of 200mg divided into two daily doses
| Study group | Role | What they receive |
|---|---|---|
| Investigational product (IP) | Experimental | Participant receiving investigational product at 200mg daily Receives: Dietary Supplement: Treatment |
| Placebo | Placebo comparator | Participant receiving placebo capsules at 200mg daily Receives: Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Blood pressure
Blood pressure in mmHg using Sphygmomanometer
Measured: Baseline, Month 3 and Month 6
Changes in Advanced Glycation End Products (AGEs)
Changes in blood AGEs concentration measured by ELISA will be quantified as circulating glycoxidation markers and expressed in arbitrary units (AU) or µg/mL
Measured: Baseline, Month 3, and Month 6
Changes in Protein Carbonyl
Change in blood protein carbonyl concentration measured by ELISA , will be quantified as nmol carbonyl/mg protein
Measured: Baseline, Month 3, and Month 6
Change in Malondialdehyde (MDA)
Change in blood malondialdehyde concentration measured by high-performance liquid chromatography (HPLC)
Measured: Baseline, Month 3, and Month 6
Change in DNA Damage
Change in blood DNA damage levels measured using validated laboratory assays
Measured: Baseline, Month 3, and Month 6
Body Composition assessment
Measured using Inbody 770 Analyzer at Physiology Department; BMI (kg/m²) calculated from weight (kg) and height (m); Body fat percentage (%); visceral fate (cm²); basal metabolic rate (kcal); waist to hip ratio
Measured: Baseline, Month 3, and Month 6
Food intake questionnaire
Food frequency questionnaires (FFQ) will be completed by the participants, and analyse through Diet Information Management System; Result reported for carbohydrate (g), Cholesterol (mg), Energy (kcal), Fat (g), Fibre (g), Protein (g), vitamin E (mg), water (g)
Measured: Baseline, Month 3, and Month 6
Changes in SASP Gene expression
Change in senescence-associated secretory phenotype (SASP) gene expression levels in peripheral blood measured by quantitative real-time polymerase chain reaction (qRT-PCR)
Measured: Baseline, Month 3, and Month 6
Change in SASP Protein expression
Change in senescence-associated secretory phenotype (SASP) protein expression levels in peripheral blood measured using protein array analysis
Measured: Baseline, Month 3, and Month 6
Change in Tumor Necrosis Factor-Alpha (TNF-α)
Change in blood TNF-α concentration measured by enzyme-linked immunosorbent assay (ELISA), qill be quantified in picograms per millilitre (pg/mL).
Measured: Baseline, Month 3, and Month 6
Change in Inteleukin-6 (IL-6)
Change in blood IL-6 concentration measured by enzyme-linked immunosorbent assay (ELISA)
Measured: Baseline, Month 3, and Month 6
Change in ATP production
Change in mitochondrial ATP production in peripheral blood measured using Seahorse analysis
Measured: Baseline, Month 3, and Month 6
Change in Mitochondrial Complex V Enzyme Activity
Change in mitochondrial Complex V enzyme activity measured in peripheral blood samples
Measured: Baseline, Month 3, and Month 6
Change in Mitochondrial Membrane Potential
Changes in mitochondrial membrane potential measured in peripheral blood samples
Measured: Baseline, Month 3, and Month 6
Change in Plasma Alpha-Tocotrienol Concentration
Change in plasma α-tocotrienol concentration measured by HPLC will be quantified in micromoles per litre (µmol/L) or micrograms per millilitre (µg/mL).
Measured: Baseline, Month 3, and Month 6
Change in Plasma Gamma- Tocotrienol Concentration
Change in plasma γ-tocotrienol concentration measured by HPLC will be quantified in micromoles per litre (µmol/L) or micrograms per millilitre (µg/mL).
Measured: Baseline, Month 3, and Month 6
Change in Total Plasma Tocotrienol Concentration
Change in total plasma tocotrienol concentration measured by HPLC will be quantified in micromoles per litre (µmol/L) or micrograms per millilitre (µg/mL).
Measured: Baseline, Month 3, and Month 6
Secondary outcomes (15)
Muscle mass
Appendicular lean mass in kilograms, kg will be measured using Dual-Energy X-ray Absorptiometry, (DEXA)
Measured: Baseline and Month 6
Fat mass
Fat mass in gram, g will be measured using Dual-Energy X-ray Absorptiometry, (DEXA)
Measured: Baseline and Month 6
Bone mineral content (BMC)
Bone mineral content in gram, g will be measured using Dual-Energy X-ray Absorptiometry, (DEXA)
Measured: Baseline and Month 6
Cognitive Function
The assessment instrument, the Montreal Cognitive Assessment (MoCA) test will be administered. The evaluation involves assessing participants through questions and instructions covering executive and spatial cognitive domains. The maximum score is 30. A score of 26 and above indicates no cognitive impairment.
Measured: Baseline and Month 6
Recall memory function
The Rey Auditory Verbal Learning Test (RAVLT) will be utilized. the RAVLT includes two distinct word lists (A and B). Participants will recall the items from list A over five trials (Memory A1 to A5). Following this, an interference list (list B), comprising 15 unrelated nouns, will be introduced, and participants will attempt to recall as many words as possible from it. Subsequently, participants will be asked to recall the words from list A (Delayed recall/memory A6) without the examiner repeating the list. The number of correctly recalled words for each trial will be totaled to generate a score.
Total Learning Score (Sum of Trials A1-A5) to indicate normal performance: 45-65, Mild Cognitive impairment: 30-45, dementia: below 30. For delayed recall score (M6), to indicate normal performance: ≥8-12 words recalled, Mild Cognitive Impairment: 4-7 words recalled, and dementia: ≤3 words recalled
Measured: Baseline and Month 6
Working memory function
The Digit Span Test involves recalling numbers in the same order (forward), reverse order (backward), or ascending order (sequencing). The test starts with short sequences and increases in length to assess memory capacity. A higher score (20 - 30) indicates better cognitive function, while a lower score (0 - 19) may suggest attention or memory issues. The total score is 30.
Measured: Baseline and Month 6
Change in Pulse Wave Velocity (PWV)
Change in arterial stiffness assessed by pulse wave velocity using an Arteriograph device, will be recorded in metres per second (m/s)
Measured: Baseline and Month 6
Change in Augmentation Index (Aix)
Change in arterial wave reflection assessed by augmentation index using an Arteriograph device will be expressed as a percentage (%).
Measured: Baseline, and Month 6
Change in Central Blood Pressue
Change in central blood pressure measured using an Arteriograph device will be measured in millimetres of mercury (mmHg)
Measured: Baseline, and month 6
Change in Skin Elasticity
Change in skin elasticity measured using a Cutometer, quantify in Arbitary unit
Measured: Baseline and month 6
Change in Skin Hydration
Change in skin hydration measured using a Corneometer, quantify in Arbitary unit
Measured: Baseline and month 6
Change in Transepidermal Water Loss
Change in skin barrier function measured as transepidermal water loss using a Tewameter quantify in Arbitary unit
Measured: Baseline and Month 6
Change in Skin Pigmentation
Change in skin pigmentation measured using a mexameter quantify in Arbitary unit
Measured: Baseline and Month 6
Change in sebum secretion
Change in skin sebum secretion measured using a Sebumeter quantify in Arbitary unit
Measured: Baseline and Month 6
Change in Skin Wrinkle and Roughness
Change in wrinkle and skin roughness parameters measured using a visiocan quantify in Arbitary unit
Measured: Baseline and Month 6
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jun 2026
- Study start31 Oct 2023
- Primary completion19 Dec 2024
- Study completion30 Jan 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HealthyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 220 participants (estimated)
Sponsor and investigators
- Lead sponsor
- National University of Malaysia
- Sponsor type
- University, hospital or other
- Collaborators
- Malaysia Palm Oil Board, Davos Life Science Pte Ltd
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07637487
- Sponsor's protocol ID
- UKM PPI/111/8/JEP-2022-676
- Status last verified
- Jun 2026
- First submitted
- 29 Dec 2025
- Last updated
- 9 Jun 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: All IPD that underlie results in a publication
Study at a glance
From the registry record, last updated by the sponsor on 9 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Evaluating Tocotrienol-Rich Fraction as a Senolytic Agent in Middle-Aged Adults
- ClinicalTrials.gov ID
- NCT07637487
- Acronym / sponsor ID
- UKM PPI/111/8/JEP-2022-676
- Conditions
- Healthy
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 220 participants (estimated)
- Lead sponsor
- National University of MalaysiaUniversity, hospital or other
- Collaborators
- Malaysia Palm Oil Board, Davos Life Science Pte Ltd
- Study start
- 31 Oct 2023 (actual)
- Primary completion
- 19 Dec 2024 (actual)
- Study completion
- 30 Jan 2027 (estimated)
- First posted
- 9 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to determine whether tocotrienol works as a senolytic agent to delay age-related biological changes in middle-aged adults. The study will also evaluate the safety of tocotrienol supplementation. The main questions it aims to answer are:
Does tocotrienol reduce markers of cellular senescence, inflammation, oxidative stress, and mitochondrial dysfunction?
What health changes or medical issues occur in participants taking tocotrienol?
Researchers will compare tocotrienol-rich fraction to a placebo (a look-alike capsule with no active ingredient) to determine whether tocotrienol is effective in modulating aging-related pathways.
Participants will:
Take tocotrienol (200 mg/day) or a placebo daily for 6 months
Attend study visits at baseline, 3 months, and 6 months for clinical assessments and laboratory tests
Undergo blood sampling and health evaluations, including measures of senescence-associated secretory phenotype (SASP), inflammation, oxidative stress, mitochondrial function, vascular health, skin status, cognitive function, body composition, and bone mineral density.
Complete questionnaires related to diet throughout the study period
This study aims to provide clinical evidence on the potential of tocotrienol as a senolytic intervention for promoting healthy aging and reducing the risk of age-related diseases.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Investigational product (IP) | Experimental | Dietary Supplement: TreatmentParticipant receiving investigational product at 200mg daily |
| Placebo | Placebo comparator | Other: PlaceboParticipant receiving placebo capsules at 200mg daily |
Who may qualify
- Ages
- 35 to 50 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (7 listed)
- Generally healthy as assessed by physical examination and blood lab test, including adequate liver and renal function, Neutrophil count > 1500/mm3, Platelet count 120,000 - 450,000/mm3, Haemoglobin concentration 11.5 to 19.0g/dL for men; 10.5-17.5 g/dL for women, Prothrombin and partial thromboplastin time within normal range, ALT and AST < 80 IU/L, Creatinine 0.7 to 1.3 mg/dL
- Subject of either gender, 35 to 64 years of age (inclusive)
- Not allergy to palm oil and vitamin E
- Do not take vitamin E supplements over the past 3 months
- Provide written informed consent prior to screening
Key exclusion criteria (11 listed)
- Subjects with fat malabsorption
- Subjects with chronic conditions such as cardiac diseases (heart failure, myocardial infraction, ischemic heart disease), neurological diseases, diabetes, HIV infection, psychiatric illness/social situations
- Subjects with vegan diet
- Current smoker or used to smoke in the past 3 months
- Subject for surgery or had undergone surgery in the past 3 months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TreatmentEach participant will receive 200mg/day of tocotrienol-rich fraction capsules divided into two daily doses | Dietary supplement | Investigational product (IP) |
| PlaceboParticipant will receive placebo softgel of 200mg divided into two daily doses | Other | Placebo |
Primary outcome
Blood pressure
Time frame: Baseline, Month 3 and Month 6
Blood pressure in mmHg using Sphygmomanometer
Changes in Advanced Glycation End Products (AGEs)
Time frame: Baseline, Month 3, and Month 6
Changes in blood AGEs concentration measured by ELISA will be quantified as circulating glycoxidation markers and expressed in arbitrary units (AU) or µg/mL
Changes in Protein Carbonyl
Time frame: Baseline, Month 3, and Month 6
Change in blood protein carbonyl concentration measured by ELISA , will be quantified as nmol carbonyl/mg protein
Change in Malondialdehyde (MDA)
Time frame: Baseline, Month 3, and Month 6
Change in blood malondialdehyde concentration measured by high-performance liquid chromatography (HPLC)
Change in DNA Damage
Time frame: Baseline, Month 3, and Month 6
Change in blood DNA damage levels measured using validated laboratory assays
Body Composition assessment
Time frame: Baseline, Month 3, and Month 6
Measured using Inbody 770 Analyzer at Physiology Department; BMI (kg/m²) calculated from weight (kg) and height (m); Body fat percentage (%); visceral fate (cm²); basal metabolic rate (kcal); waist to hip ratio
Food intake questionnaire
Time frame: Baseline, Month 3, and Month 6
Food frequency questionnaires (FFQ) will be completed by the participants, and analyse through Diet Information Management System; Result reported for carbohydrate (g), Cholesterol (mg), Energy (kcal), Fat (g), Fibre (g), Protein (g), vitamin E (mg), water (g)
Changes in SASP Gene expression
Time frame: Baseline, Month 3, and Month 6
Change in senescence-associated secretory phenotype (SASP) gene expression levels in peripheral blood measured by quantitative real-time polymerase chain reaction (qRT-PCR)
Change in SASP Protein expression
Time frame: Baseline, Month 3, and Month 6
Change in senescence-associated secretory phenotype (SASP) protein expression levels in peripheral blood measured using protein array analysis
Change in Tumor Necrosis Factor-Alpha (TNF-α)
Time frame: Baseline, Month 3, and Month 6
Change in blood TNF-α concentration measured by enzyme-linked immunosorbent assay (ELISA), qill be quantified in picograms per millilitre (pg/mL).
Change in Inteleukin-6 (IL-6)
Time frame: Baseline, Month 3, and Month 6
Change in blood IL-6 concentration measured by enzyme-linked immunosorbent assay (ELISA)
Change in ATP production
Time frame: Baseline, Month 3, and Month 6
Change in mitochondrial ATP production in peripheral blood measured using Seahorse analysis
Change in Mitochondrial Complex V Enzyme Activity
Time frame: Baseline, Month 3, and Month 6
Change in mitochondrial Complex V enzyme activity measured in peripheral blood samples
Change in Mitochondrial Membrane Potential
Time frame: Baseline, Month 3, and Month 6
Changes in mitochondrial membrane potential measured in peripheral blood samples
Change in Plasma Alpha-Tocotrienol Concentration
Time frame: Baseline, Month 3, and Month 6
Change in plasma α-tocotrienol concentration measured by HPLC will be quantified in micromoles per litre (µmol/L) or micrograms per millilitre (µg/mL).
Change in Plasma Gamma- Tocotrienol Concentration
Time frame: Baseline, Month 3, and Month 6
Change in plasma γ-tocotrienol concentration measured by HPLC will be quantified in micromoles per litre (µmol/L) or micrograms per millilitre (µg/mL).
Change in Total Plasma Tocotrienol Concentration
Time frame: Baseline, Month 3, and Month 6
Change in total plasma tocotrienol concentration measured by HPLC will be quantified in micromoles per litre (µmol/L) or micrograms per millilitre (µg/mL).
15 secondary outcomes
Muscle mass
Time frame: Baseline and Month 6
Fat mass
Time frame: Baseline and Month 6
Bone mineral content (BMC)
Time frame: Baseline and Month 6
Cognitive Function
Time frame: Baseline and Month 6
Recall memory function
Time frame: Baseline and Month 6
Working memory function
Time frame: Baseline and Month 6
Change in Pulse Wave Velocity (PWV)
Time frame: Baseline and Month 6
Change in Augmentation Index (Aix)
Time frame: Baseline, and Month 6
Change in Central Blood Pressue
Time frame: Baseline, and month 6
Change in Skin Elasticity
Time frame: Baseline and month 6
Change in Skin Hydration
Time frame: Baseline and month 6
Change in Transepidermal Water Loss
Time frame: Baseline and Month 6
Change in Skin Pigmentation
Time frame: Baseline and Month 6
Change in sebum secretion
Time frame: Baseline and Month 6
Change in Skin Wrinkle and Roughness
Time frame: Baseline and Month 6
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Jun 2026.
- Individual participant dataSharing planned: Yes. All IPD that underlie results in a publication
Related trials for Healthy
Recruiting
Trained vs. Untrained: Lower Extremity Pressure Changes
Trained Athletes, Untrained
Not yet recruitingPhase 1
Comparison of Pharmacokinetic/Pharmacodynamic Characteristics and Safety of GZR101-80 Injection With Separately Injected, Simultaneous Doses of GZR33 Injection and Insulin Aspart
Healthy Participants
Active, not recruitingPhase 2
Effect of Equol Supplementation on Arterial Stiffness and Cognition in Healthy Volunteers
Arterial Stiffness, White Matter Lesions
Enrolling by invitationObservational study
Screening for Hematology Branch Protocols
Hematologic Disease and Disorders, Donors
RecruitingPhase 1
A Study of Single and Multiple Subcutaneous or Intravenous Doses of ADX-001 in Healthy Adults to Assess Safety, Effects, and Immune Response
Healthy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Treatment in people with Healthy, run by National University of Malaysia at 1 site in Malaysia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 9 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Malaysia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Suzana Makpol (603-91459554, suzanamakpol@ukm.edu.my), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Blood pressure (time frame: Baseline, Month 3 and Month 6). The study lists 17 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jun 2026.